HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 3-9

  Tsompanidi, Eirini M ^a   Brinkmeier, Maria S ^a   Fotiadou, Elisavet H ^a   Giakoumi, Smaragda M ^a   Kypreos, Kyriakos E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Anti atherogenic functions; Apolipoprotein AI; Apolipoprotein CIII; Apolipoprotein E; Atherosclerosis; HDL biogenesis; HDL functions; HDL quality; HDL quantity; High density lipoprotein

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TORCETRAPIB;

ATHEROSCLEROSIS; BIOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; DYSLIPIDEMIA; HEART DISEASE; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ATHEROSCLEROSIS; CORONARY DISEASE; HUMANS; LIPOPROTEINS, HDL;

EID: 73649134029     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.034     Document Type: Review

References (109)

1. American Heart Association. Heart and stroke facts: 2001 statistical supplement (2000), American Heart Association
2. Fonarow G.C. The global burden of atherosclerotic vascular disease. Nat Clin Pract Cardiovasc Med 4 (2007) 530-531
3. Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
4. Gimbrone Jr. M.A. Vascular endothelium, hemodynamic forces, and atherogenesis. Am J Pathol 155 (1999) 1-5
5. Neaton J.D., and Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152 (1992) 56-64
6. Pearson T.A., LaCroix A.Z., Mead L.A., and Liang K.Y. The prediction of midlife coronary heart disease and hypertension in young adults: the Johns Hopkins multiple risk equations. Am J Prev Med 6 (1990) 23-28
7. Soloff L.A. Intermediate lipoproteins, atherosclerosis, and Gofman. Circulation 97 (1998) 708
8. Gordon T., Castelli W.P., Hjortland M.C., et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 (1977) 707-714
9. Cybulsky M.I., and Gimbrone Jr. M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251 (1991) 788-791
10. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
11. Peters W., and Charo I.F. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol 12 (2001) 175-180
12. Navab M., Berliner J.A., Watson A.D., et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 16 (1996) 831-842
13. Han K.H., Han K.O., Green S.R., and Quehenberger O. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J Lipid Res 40 (1999) 1053-1063
14. Yamada Y., Doi T., Hamakubo T., and Kodama T. Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol Life Sci 54 (1998) 628-640
15. Horkko S., Binder C.J., Shaw P.X., et al. Immunological responses to oxidized LDL. Free Radic Biol Med 28 (2000) 1771-1779
16. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
17. Virmani R., Kolodgie F.D., Burke A.P., et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20 (2000) 1262-1275
18. Getz G.S. When is atherosclerosis not atherosclerosis?. Arterioscler Thromb Vasc Biol 20 (2000) 1694
19. Reardon C.A., and Getz G.S. Mouse models of atherosclerosis. Curr Opin Lipidol 12 (2001) 167-173
20. Glass C.K., and Witztum J.L. Atherosclerosis. The road ahead. Cell 104 (2001) 503-516
21. Curtiss L.K., and Boisvert W.A. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 11 (2000) 243-251
22. Hansson G.K. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 8 (1997) 301-311
23. Colles S.M., Irwin K.C., and Chisolm G.M. Roles of multiple oxidized LDL lipids in cellular injury: dominance of 7 beta-hydroperoxycholesterol. J Lipid Res 37 (1996) 2018-2028
24. Lee R.T., and Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 17 (1997) 1859-1867
25. Faber B.C., Heeneman S., Daemen M.J., and Cleutjens K.B. Genes potentially involved in plaque rupture. Curr Opin Lipidol 13 (2002) 545-552
26. National Cholesterol Education Program (NCEP) Expert Panel on Detection EaToHBCiAATPI. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
27. Zannis V.I., Kypreos K.E., Chroni A., Kardassis D., and Zanni E.E. In: Loscalzo J. (Ed). Molecular mechanisms of atherosclerosis (2004), Taylor & Francis, New York, NY 111-174
28. Nolte R.T., and Atkinson D. Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism. Biophys J 63 (1992) 1221-1239
29. Borhani D.W., Rogers D.P., Engler J.A., and Brouillette C.G. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 94 (1997) 12291-12296
30. Segrest J.P., Li L., Anantharamaiah G.M., et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 11 (2000) 105-115
31. Soutar A.K., Garner C.W., Baker H.N., et al. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry 14 (1975) 3057-3064
32. Chroni A., Liu T., Gorshkova I., et al. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J Biol Chem 278 (2003) 6719-6730
33. Fitzgerald M.L., Morris A.L., Chroni A., et al. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. J Lipid Res 45 (2004) 287-294
34. Timmins J.M., Lee J.Y., Boudyguina E., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115 (2005) 1333-1342
35. Brunham L.R., Kruit J.K., Iqbal J., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 116 (2006) 1052-1062
36. Van Eck M., Pennings M., Hoekstra M., et al. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 16 (2005) 307-315
37. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108 (2001) 793-797
38. Liu T., Krieger M., Kan H.Y., and Zannis V.I. The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J Biol Chem 277 (2002) 21576-21584
39. Kypreos K.E., and Zannis V.I. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J 403 (2007) 359-367
40. Kypreos K.E. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia. Biochemistry 47 (2008) 10491-10502
41. Zannis V.I., Chroni A., Kypreos K.E., et al. Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer. Curr Opin Lipidol 15 (2004) 151-166
42. Zannis V.I., and Breslow J.L. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 20 (1981) 1033-1041
43. Kypreos K.E., Teusink B., Van Dijk K.W., et al. Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer. FASEB J 15 (2001) 1598-1600
44. Yamamoto T., Choi H.W., and Ryan R.O. Apolipoprotein E isoform-specific binding to the low-density lipoprotein receptor. Anal Biochem 372 (2008) 222-226
45. Kypreos K.E., and Zannis V.I. LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J Lipid Res 47 (2006) 521-529
46. Veniant M.M., Zlot C.H., Walzem R.L., et al. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice. J Clin Invest 102 (1998) 1559-1568
47. Fazio S., Linton M.F., Hasty A.H., and Swift L.L. Recycling of apolipoprotein E in mouse liver. J Biol Chem 274 (1999) 8247-8253
48. Rensen P.C., Jong M.C., van Vark L.C., et al. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem 275 (2000) 8564-8571
49. Farkas M.H., Swift L.L., Hasty A.H., et al. The recycling of apolipoprotein E in primary cultures of mouse hepatocytes. Evidence for a physiologic connection to high density lipoprotein metabolism. J Biol Chem 278 (2003) 9412-9417
50. Ishibashi S., Perrey S., Chen Z., et al. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem 271 (1996) 22422-22427
51. Ishibashi S., Brown M.S., Goldstein J.L., et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92 (1993) 883-893
52. Linton M.F., and Fazio S. Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. Curr Opin Lipidol 10 (1999) 97-105
53. Hasty A.H., Linton M.F., Brandt S.J., et al. Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation 99 (1999) 2571-2576
54. Thorngate F.E., Rudel L.L., Walzem R.L., and Williams D.L. Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 20 (2000) 1939-1945
55. Shimano H., Ohsuga J., Shimada M., et al. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 95 (1995) 469-476
56. Tsukamoto K., Tangirala R., Chun S.H., et al. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19 (1999) 2162-2170
57. Tsukamoto K., Tangirala R.K., Chun S., et al. Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. Mol Ther 1 (2000) 189-194
58. Desurmont C., Caillaud J.M., Emmanuel F., et al. Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice. Arterioscler Thromb Vasc Biol 20 (2000) 435-442
59. Raffai R.L., Loeb S.M., and Weisgraber K.H. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 25 (2005) 436-441
60. Chroni A., Nieland T.J., Kypreos K.E., et al. SR-BI mediates cholesterol efflux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry 44 (2005) 13132-13143
61. Karlsson H., Leanderson P., Tagesson C., and Lindahl M. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5 (2005) 551-565
62. Karlsson H., Leanderson P., Tagesson C., and Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5 (2005) 1431-1445
63. Heller M., Stalder D., Schlappritzi E., et al. Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics 5 (2005) 2619-2630
64. Rezaee F., Casetta B., Levels J.H., et al. Proteomic analysis of high-density lipoprotein. Proteomics 6 (2006) 721-730
65. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117 (2007) 746-756
66. Davidson W.S., Silva R.A., Chantepie S., et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters. Relevance to antioxidative function. Arterioscler Thromb Vasc Biol (2009)
67. Bruce C., Chouinard Jr. R.A., and Tall A.R. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 18 (1998) 297-330
68. Sviridov D., and Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 161 (2002) 245-254
69. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl. (1996) S11-S20
70. Navab M., Hama S.Y., Anantharamaiah G.M., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41 (2000) 1495-1508
71. Navab M., Imes S.S., Hama S.Y., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88 (1991) 2039-2046
72. Navab M., Hama S.Y., Cooke C.J., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41 (2000) 1481-1494
73. Navab M., Reddy S., Van Lenten B.J., et al. Role of dysfunctional HDL in atherosclerosis. J Lipid Res 50 (2008) S145-S149
74. Nofer J.R., van der G.M., Tolle M., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113 (2004) 569-581
75. Sviridov D., Mukhamedova N., Remaley A.T., et al. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 15 (2008) 52-62
76. Barter P.J., Nicholls S., Rye K.A., et al. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
77. Norata G.D., Callegari E., Marchesi M., et al. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 111 (2005) 2805-2811
78. Wadham C., Albanese N., Roberts J., et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109 (2004) 2116-2122
79. Jambou D., Dejour N., Bayer P., et al. Effect of human native low-density and high-density lipoproteins on prostaglandin production by mouse macrophage cell line P388D1: possible implications in pathogenesis of atherosclerosis. Biochim Biophys Acta 1168 (1993) 115-121
80. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 (2001) 481-488
81. -/- mice. FASEB J 14 (2000) 2032-2039
82. Kanji S.S., Kuohung W., Labaree D.C., and Hochberg R.B. Regiospecific esterification of estrogens by lecithin:cholesterol acyltransferase. J Clin Endocrinol Metab 84 (1999) 2481-2488
83. Gong M., Wilson M., Kelly T., et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 111 (2003) 1579-1587
84. Badeau R.M., Metso J., Tikkanen M.J., and Jauhiainen M. High-density lipoprotein-associated 17beta-estradiol fatty acyl ester uptake by Fu5AH hepatoma cells: implications of the roles of scavenger receptor class B, type I and the low-density lipoprotein receptor. Biochim Biophys Acta 1771 (2007) 1329-1334
85. Seetharam D., Mineo C., Gormley A.K., et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 98 (2006) 63-72
86. Tso C., Martinic G., Fan W.H., et al. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol 26 (2006) 1144-1149
87. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22 (1999) 336-345
88. Han R., Lai R., Ding Q., et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50 (2007) 1960-1968
89. Miller N.E., Thelle D.S., Forde O.H., and Mjos O.D. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1 (1977) 965-968
90. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
91. Shah P.K., and Amin J. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 85 (1992) 1279-1285
92. Wilson P.W., Abbott R.D., and Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8 (1988) 737-741
93. Forte T.M., Nichols A.V., Krauss R.M., and Norum R.A. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J Clin Invest 74 (1984) 1601-1613
94. Gordon D.J., and Rifkind B.M. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321 (1989) 1311-1316
95. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992) 37-45
96. Manttari M., Huttunen J.K., Koskinen P., et al. Lipoproteins and coronary heart disease in the Helsinki Heart Study. Eur Heart J 11 Suppl. H (1990) 26-31
97. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299 (2008) 2524-2532
98. Roma P., Gregg R.E., Meng M.S., et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. J Clin Invest 91 (1993) 1445-1452
99. Roberts C.K., Ng C., Hama S., et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 101 (2006) 1727-1732
100. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
101. Badimon J.J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
102. Duverger N., Kruth H., Emmanuel F., et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94 (1996) 713-717
103. Trigatti B., Rayburn H., Vinals M., et al. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc Natl Acad Sci USA 96 (1999) 9322-9327
104. Kozarsky K.F., Donahee M.H., Glick J.M., et al. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 20 (2000) 721-727
105. Webb N.R., Cai L., Ziemba K.S., et al. The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res 43 (2002) 1890-1898
106. Connelly P.W., and Hegele R.A. Hepatic lipase deficiency. Crit Rev Clin Lab Sci 35 (1998) 547-572
107. Asztalos B.F., and Schaefer E.J. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 91 (2003) 12E-17E
108. Castelli W.P., Anderson K., Wilson P.W., and Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 2 (1992) 23-28
109. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 248 (1982) 1465-1477